Takeda Pharmaceuticals America, Inc.

Takeda Pharmaceuticals America, Inc., a Cambridge, Massachusetts-based subsidiary of Japan-based Takeda Pharmaceutical Company Limited, manufactures and supplies specialized biopharmaceutical products—including treatments for hereditary angioedema, hemophilia, immune disorders, and rare metabolic conditions—to federal healthcare agencies as a prime contractor with no set-aside designations. The vendor is foreign-owned and operates exclusively in full-and-open competition, competing on the specialized and often single-source nature of its pharmaceutical portfolio.

Takeda's federal footprint centers on the supply of nine advanced therapeutic agents: CINRYZE and KALBITOR for hereditary angioedema; ADVATE and OBIZUR for hemophilia; GAMMAGARD and immune globulin products for immunological conditions; TAKHZYRO for rare genetic disorders; LIVTENCITY for transplant-related infections; and GATTEX for short bowel syndrome. The vendor anchors its business to the GSA Pharmaceuticals and Drugs Schedule (FSS-61-IB), from which it executes hundreds of delivery orders to healthcare agencies across the federal government. Representative awards include a $107,540 delivery order to Veterans Integrated Service Network 20 for Gammagard Liquid (April 2026); a $548,689 delivery order to the Federal Correctional Institution Fort Worth for pharmacy services (April 2026); and a $204,577 delivery order also to Fort Worth for January-through-September 2026 pharmacy operations (February 2026).

Customer concentration is heavily skewed toward correctional and VA facilities. The top five customers by award count account for 73% of recent awards and are dominated by the Federal Correctional Institution Fort Worth (40 awards, $5.6 million combined potential value), Veterans Integrated Service Network 21 (22 awards, $1.3 million), Veterans Integrated Service Network 20 (13 awards, $1.3 million), Veterans Integrated Service Network 19 (12 awards, $198 thousand), and Veterans Integrated Service Network 5 (11 awards, $354 thousand). However, the potential-value ranking diverges sharply: Veterans Integrated Service Network 12 carries $898.8 million in combined potential value across just five awards, and the VA National Acquisition Center carries $214.3 million across three awards—reflecting the massive ceiling value of Takeda's primary vehicle. The combined potential value across all 135 awards reaches $1.12 billion, though only $10.5 million (1% of potential) has been obligated to date.

Takeda holds a single-award Blanket Purchase Agreement with the Department of Veterans Affairs National Acquisition Center valued at $131.0 million, effective July 15, 2025, through March 12, 2026, under the GSA Pharmaceuticals and Drugs Schedule. This BPA covers the nine therapeutic agents named above and streamlines procurement across Veterans Integrated Service Networks and authorized federal healthcare entities through delivery orders that bypass individual competitive procurements. The vendor executes 126 task orders against the Pharmaceuticals and Drugs parent vehicle, generating $160.8 million in combined potential value. All work is performed in Lexington, Massachusetts and brooks, Kentucky, with performance specifications tied to delivery of pre-negotiated, single-source biopharmaceutical products.

Activity has grown materially: 19 awards in 2022 to 37 in 2024, with a slight dip to 26 in 2025 and 11 in 2026 year-to-date. Only six awards (combined potential value $1 million) face ultimate completion within the next twenty-four months, limiting near-term recompete exposure for the vendor. Takeda operates entirely as a prime contractor—all 135 awards in the source are prime awards with zero subcontract work—and does not appear on any broader government-wide or agency-wide IDIQs outside the GSA pharmaceuticals vehicle. The vendor's federal profile is singular: it is a specialized pharmaceutical supplier competing on the scientific uniqueness and limited-source nature of its drugs rather than on price or procurement vehicle breadth. The concentration of awards at correctional facilities and VA medical centers, combined with the single-source character of rare-disease pharmaceuticals, insulates Takeda from typical competitive pressure and set-aside constraints that govern most federal contracting.